Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Clinical Utility of Antipeptidyl Arginine Deiminase Type 4 Antibodies.

Darrah E, Martinez-Prat L, Mahler M.

J Rheumatol. 2019 Jan 15. pii: jrheum.180905. doi: 10.3899/jrheum.180905. [Epub ahead of print]

PMID:
30647163
2.

Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis.

Darrah E, Yu F, Cappelli LC, Rosen A, O'Dell JR, Mikuls TR.

Arthritis Rheumatol. 2018 Dec 3. doi: 10.1002/art.40791. [Epub ahead of print]

PMID:
30507066
3.

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Darrah E, Giles JT, Davis RL, Naik P, Wang H, Konig MF, Cappelli LC, Bingham CO 3rd, Danoff SK, Andrade F.

Front Immunol. 2018 Nov 20;9:2696. doi: 10.3389/fimmu.2018.02696. eCollection 2018.

4.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

5.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

6.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

7.

Rheumatoid arthritis and citrullination.

Darrah E, Andrade F.

Curr Opin Rheumatol. 2018 Jan;30(1):72-78. doi: 10.1097/BOR.0000000000000452. Review.

8.

Distorted Immunodominance by Linker Sequences or other Epitopes from a Second Protein Antigen During Antigen-Processing.

Kim A, Boronina TN, Cole RN, Darrah E, Sadegh-Nasseri S.

Sci Rep. 2017 Apr 19;7:46418. doi: 10.1038/srep46418.

9.

Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.

Navarro-Millán I, Darrah E, Westfall AO, Mikuls TR, Reynolds RJ, Danila MI, Curtis JR; CLEAR Investigators, Rosen A, Bridges SL Jr.

Arthritis Res Ther. 2016 Oct 22;18(1):241.

10.

Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis.

Darrah E, Kim A, Zhang X, Boronina T, Cole RN, Fava A, Giles JT, Bingham III CO, Chalmers MJ, Griffin PR, Sadegh-Nasseri S, Rosen A.

J Proteome Res. 2017 Jan 6;16(1):355-365. doi: 10.1021/acs.jproteome.6b00617. Epub 2016 Oct 20.

11.

Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.

Seaman A, Darrah E, Infantino M, Meacci F, Manfredi M, Benucci M, Mahler M.

Autoimmun Rev. 2016 Jul;15(7):776-80. doi: 10.1016/j.autrev.2016.03.016. Epub 2016 Mar 18. Review.

PMID:
26997641
12.

Editorial: citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh my! Entering the forest of autoantigen modifications in rheumatoid arthritis.

Darrah E, Andrade F.

Arthritis Rheumatol. 2015 Mar;67(3):604-8. doi: 10.1002/art.38970. No abstract available.

13.

Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.

Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, Bathon JM.

PLoS One. 2014 Jun 5;9(6):e98794. doi: 10.1371/journal.pone.0098794. eCollection 2014.

15.

Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A.

Science. 2014 Jan 10;343(6167):152-7. doi: 10.1126/science.1246886. Epub 2013 Dec 5.

16.

Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis.

Romero V, Fert-Bober J, Nigrovic PA, Darrah E, Haque UJ, Lee DM, van Eyk J, Rosen A, Andrade F.

Sci Transl Med. 2013 Oct 30;5(209):209ra150. doi: 10.1126/scitranslmed.3006869.

17.

Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.

Ferucci ED, Darrah E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM, Fritzler MJ, Rosen A, El-Gabalawy HS.

J Rheumatol. 2013 Sep;40(9):1523-8. doi: 10.3899/jrheum.130293. Epub 2013 Aug 1.

18.

Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity.

Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A.

Sci Transl Med. 2013 May 22;5(186):186ra65. doi: 10.1126/scitranslmed.3005370.

19.

NETs: the missing link between cell death and systemic autoimmune diseases?

Darrah E, Andrade F.

Front Immunol. 2013 Jan 17;3:428. doi: 10.3389/fimmu.2012.00428. eCollection 2012.

20.

Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.

Darrah E, Rosen A, Giles JT, Andrade F.

Ann Rheum Dis. 2012 Jan;71(1):92-8. doi: 10.1136/ard.2011.151712. Epub 2011 Aug 21.

Supplemental Content

Loading ...
Support Center